Showing 6411-6420 of 9765 results for "".
- Analysis: Drug Class Influences Clinical Management of Eruptive Keratoacanthoma/Squamous Cell Carcinomahttps://practicaldermatology.com/news/drug-class-influences-clinical-profile-and-management-of-eruptive-kascc/2474440/The clinical features and management of drug-induced eruptive keratoacanthoma (KA) and squamous cell carcinoma (SCC) differ significantly depending on the causative drug class, according to a new analysis of 172 reported cases.
- From ASLMS: Advances in Infantile Hemangioma Diagnosis and Carehttps://practicaldermatology.com/news/from-aslms-advances-in-infantile-hemangioma-diagnosis-and-care/2474328/New guidelines from the International Society for the Study of Vascular Anomalies (ISSVA) offer more precise classification and improved multidisciplinary pathways for patient care. Kristen Kelly, MD, Professor of Dermatology and Surgery a
- Ivarmacitinib Demonstrates Efficacy in Phase 3 Trial for Atopic Dermatitishttps://practicaldermatology.com/news/ivarmacitinib-demonstrates-efficacy-in-phase-3-trial-for-atopic-dermatitis/2474409/A new Phase 3 randomized clinical trial shows that ivarmacitinib, an oral JAK1 inhibitor, significantly improves clinical signs of moderate to severe atopic dermatitis (AD) in both adolescents and adults with a favorable safety profile.
- Study Shows Prognostic Value of 40-GEP in Advanced cSCChttps://practicaldermatology.com/news/study-shows-prognostic-value-of-40-gep-in-advanced-cscc/2474383/A new multi-institutional study indicates that a 40-gene expression profile (40-GEP) test with traditional staging enhances risk stratification for cutaneous squamous cell carcinoma (cSCC), even among patients already categorized as high- or very-high-risk using Na
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://practicaldermatology.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2474319/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick sk
- Report: 5-FU and Imiquimod Combo May Offer Enhanced Actinic Keratosis Clearancehttps://practicaldermatology.com/news/report-5-fu-and-imiquimod-combo-may-offer-enhanced-actinic-keratosis-clearance/2474234/Combining 5-fluorouracil (5-FU) and imiquimod may enhance therapeutic efficacy for actinic keratoses (AK), according to emerging data. "To date, the combination of 5-FU and imiquimod, 2 of the most used monotherapies, remain
- FDA Approves Dupilumab for CSU in Adults 12 and Olderhttps://practicaldermatology.com/news/FDA-Approves-Dupilumab-CSU-Adults-12-Older/2474212/The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc. and Sanofi) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with histamine-1 (H1) ant
- Study: AD Patients Switching From Dupilumab to Upadacitinib Have Improved EASI, Itch Scoreshttps://practicaldermatology.com/news/Study-AD-Patients-Switching-From-Dupilumab-Upadacitinib-Have-Improved-EASI-Itch-Scores/2474207/Treatment of moderate-to-severe atopic dermatitis (AD) with upadacitinib in patients who received dupilumab for 16 weeks without an adequate response demonstrated improved efficacy in skin and itch endpoints, according to new research. “Switching from Dupilumab to Upadacitinib in Adults an
- CAB Gel Reduces Lesions and Preserves Skin Tone in Skin of Colorhttps://practicaldermatology.com/news/cab-gel-reduces-lesions-and-preserves-skin-tone-in-skin-of-color/2474010/A post hoc analysis of pooled Phase 2 and Phase 3 clinical trial data suggests that clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is effective and well tolerated for the treatment of moderate to severe acne in Black patients.
- Study Links Psoriasis Gene Regulation to Spatial Genome Changeshttps://practicaldermatology.com/news/study-links-psoriasis-gene-regulation-to-spatial-genome-changes/2474007/Results from a new study in the Journal of Investigative Dermatology showed how changes in the 3D chromatin architecture of CD4+ T cells contribute to immune dysregulation in psoriasis. "In this study, the 3D genomic